Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5788-5793

  Gordon, Michael S ^a   Hussey, Michael ^a   Nagle, Raymond B ^a   Lara Jr , Primo N ^a   Mack, Philip C ^a   Dutcher, Janice ^a   Samlowski, Wolfram ^a   Clark, Joseph I ^a   Quinn, David I ^a   Pan, Chong Xian ^a   Crawford, David ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; VON HIPPEL LINDAU PROTEIN; HER2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VHL PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LUNG EMBOLISM; MALE; METASTASIS; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PAPILLARY RENAL CELL CANCER; PNEUMATOSIS INTESTINALIS; PNEUMONIA; PRIORITY JOURNAL; THROMBOSIS; TREATMENT RESPONSE; CHEMISTRY; DRUG ANTAGONISM; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL RATE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 73349085260     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8821     Document Type: Article

References (21)

1. Gnarra J, Lerman M, Zbar B, et al: Genetics of renal cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22:3-8, 1995
2. Linehan M: Identification of the Von Hippel Lindau (VHL) gene: Its role in renal cancer. JAMA 273:564-570, 1995
3. Levy A, Levy N, Iliopoulos O, et al: Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 51:575-578, 1997
4. Igarashi H, Esumi M, Ishida H, et al: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95:47-53, 2002
5. Delahunt B, Eble J, McCredie M, et al: Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32:590-595, 2001
6. Motzer R, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20:2376-2381, 2002
7. Upton M, Parker R, Youmans A, et al: Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother 28:488-495, 2005
8. Choueiri T, Plantade A, Elson P, et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127-131, 2008
9. Perera A, Kleymenova E, Walker C: Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody c225 in renal cell carcinoma. Clin Cancer Res 6:1518-1523, 2000
10. Tsao M, Sakurada A, Cutz J, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
11. Cappuzzo F, Hirsch F, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
12. Beck S, Patel M, Snyder M, et al: Effect of papillary and chromophobe cell type on disease free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71-77, 2004
13. Dawson N, Guo C, Zak R, et al: A phase II trial of gefitinib (Iressa, ZD 1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10:7812-7819, 2004
14. Jermann M, Stahel R, Salzberg M, et al: A Phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57:533-539, 2006
15. Motzer R, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99-101, 2003
16. Ravaud A, Hawkins R, Gardner J, et al: Lapatinib versus hormonal therapy in patients with advanced renal cell carcinoma: A randomized phase II clinical trial. J Clin Oncol 26:2285-2291, 2008
17. Rowinsky E, Schwartz G, Gollob J, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015, 2004
18. Hainsworth J, Sosman J, Spigel D, et al: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896, 2005
19. Bukowski R, Kabbinavar F, Figlin R, et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536-4541, 2007
20. Marks J, Broderick S, Zhou O, et al: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3:111-116, 2008
21. Sergina N, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007